Scarica l'app Stockscreener
4.70
3.69%
-0.18
Pre-mercato:
4.61
-0.09
-1.91%
Precedente Chiudi:
$4.88
Aprire:
$4.99
Volume 24 ore:
174.34K
Relative Volume:
0.03
Capitalizzazione di mercato:
$17.32M
Reddito:
$513.90K
Utile/perdita netta:
$-48.50M
Rapporto P/E:
-0.1678
EPS:
-28.0101
Flusso di cassa netto:
$-28.99M
1 W Prestazione:
-18.40%
1M Prestazione:
+147.37%
6M Prestazione:
-64.22%
1 anno Prestazione:
-87.42%
Intervallo 1D:
$4.59
$4.99
Intervallo di 1 settimana:
$4.10
$6.07
Portata 52W:
$1.26
$13.54
Co Diagnostics Inc Stock (CODX) Company Profile
Nome
Co Diagnostics Inc
Settore
Industria
Telefono
(801) 438-1036
Indirizzo
2401 S FOOTHILL DRIVE, SALT LAKE CITY
Compare CODX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
4.70 | 17.32M | 513.90K | -48.50M | -28.99M | -28.01 |
ABT
Abbott Laboratories
|
89.65 | 156.15B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.64 | 117.17B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.33 | 103.13B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
47.17 | 70.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.76 | 49.38B | 6.30B | 1.07B | 1.09B | 1.8406 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-12 | Downgrade | Sidoti | Buy → Neutral |
| 2021-12-29 | Iniziato | Sidoti | Buy |
| 2021-03-29 | Downgrade | Maxim Group | Buy → Hold |
| 2020-05-20 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Co Diagnostics Inc Borsa (CODX) Ultime notizie
Co-Diagnostics Signs Exclusive Distribution Deal With Mexican Partner; Shares Rise Pre-Bell - Moomoo
Co-Diagnostics (CODX) Expands Distribution Agreement in Mexico - GuruFocus
Co-Diagnostics signs exclusive Mexico distribution deal - Investing.com
Co-Diagnostics test used in over 50% of Mexico COVID checks gets 5-year deal - Stock Titan
Co-diagnostics Company Profile & Introduction - Moomoo
CODX Q1 2026 Earnings: EPS Falls Short of Estimates as Company Continues Strategic PivotDividend Increase Stocks - newsline.com
Co-diagnostics(CODX) Stock Options Chain | Quotes & News - Moomoo
CODX Q1 2026 Earnings: Wider-than-Expected Loss as Revenue Remains NilQuarterly Earnings - newsline.com
OpenAI's Major Overhaul: Aiming for Growth Before IPO - GuruFocus
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C. - Eastern Progress
symbol__ Stock Quote Price and Forecast - CNN
Jane Street Group, LLC's Strategic Acquisition of Co-Diagnostics Inc Shares - GuruFocus
Jane Street entities report 6.4% stake in Co-Diagnostics (CODX) - Stock Titan
Co-Diagnostics (CODX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Co-Diagnostics advances Ebola PCR test development program - Investing.com UK
Co-Diagnostics (CODX) Advances Ebola PCR Development Program - GuruFocus
Co-Diagnostics advances Ebola PCR test development program By Investing.com - Investing.com South Africa
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities - StreetInsider
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities – Company AnnouncementFT.com - Financial Times
Q4 2025 Co-Diagnostics Inc Earnings Call Transcript - GuruFocus
Q1 2026 Co-Diagnostics Inc Earnings Call Transcript - GuruFocus
[EFFECT] Co-Diagnostics, Inc. SEC Filing - Stock Titan
Is Co-Diagnostics National Security's next diagnostic pick? - MSN
Co-Diagnostics develops Ebola assay strategy following WHO emergency alert (CODX) - MSN
CODX - Finviz
$Co-diagnostics (CODX.US)$ Fuhh... - Moomoo
Co-Diagnostics: Offering Expected to Close on or About May 21 >CODX - Moomoo
Co-Diagnostics (CODX) registers 4.94M shares for resale; up to $5.18M possible - Stock Titan
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - Investing.com
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - MarketBeat
$Co-diagnostics (CODX.US)$ more the boyzzz want - Moomoo
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript - AOL.com
Co-Diagnostics (NASDAQ: CODX) CEO nets RSU shares after tax sale - Stock Titan
Co-Diagnostics (NASDAQ: CODX) CFO reports RSU vesting and tax-related share sale - Stock Titan
Co-Diagnostics (NASDAQ: CODX) president nets RSU shares after tax sale - Stock Titan
Co-Diagnostics (CODX) director receives 1,695-share equity grant - Stock Titan
Director at Co-Diagnostics (NASDAQ: CODX) receives 1,695-share equity grant - Stock Titan
[Form 4] Co-Diagnostics, Inc. Insider Trading Activity - Stock Titan
Co-Diagnostics (NASDAQ: CODX) director awarded 1,695 shares and exercises RSUs - Stock Titan
$Co-diagnostics (CODX.US)$ - Moomoo
Co-Diagnostics (CODX) Enhances PCR Assay Development for Ebola O - GuruFocus
Co-Diagnostics Shares Surge as Investors React to Ebola-test Development Update and Outbreak Headlines - Moomoo
Co-Diagnostics shares surge as investors react to Ebola-test development update and outbreak headlines - Quiver Quantitative
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet - Yahoo Finance
Co-Diagnostics Advances Ebola Pcr Assay Development Strategy with Joint Venture Cosara - marketscreener.com
21.00 🙏 - Moomoo
CODX Stock Rockets As Saudi Facility And Ebola Assay Shift Outlook - StocksToTrade
Co-Diagnostics stock surges on Ebola test development plan By Investing.com - Investing.com Nigeria
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara - Quantisnow
Co-Diagnostics stock surges on Ebola test development plan - Investing.com
Co Diagnostics Inc Azioni (CODX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.17%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):